Mouse Anti-Human IL-6 BioActive Antibody, Clone B-E8, Azide free

Contact us
Diaclone
Product Code: 855.050.000
Product Group: Primary Antibodies
Supplier: Diaclone
CodeSizePrice
855.050.000200ug/200ul£232.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Mouse
Antibody Isotype: IgG1
Antibody Clonality: Monoclonal
Antibody Clone: B-E8
Regulatory Status: RUO
Target Species: Human

Further Information

Activity:
Inhibits IL-6 induced proliferation on XG1 cell line
Antigen:
IL-6
Biological Acivity:
Inhibits IL-6 induced proliferation on XG1 Cell line
Conjugate:
Azide free
Format:
Azide free
Hybridoma:
Myeloma X63/AG.8653 x Balb/c spleen cells
Immunisation:
Recombinant human IL-6
Reactivity:
Human
Research Area:
Cytokines / Growth Factors
Specificity:
Recognises both natural and recombinant human IL-6

References

  1. Adam N. et al. J. Virol.2009; JVI.01601-08.. Unraveling Viral Interleukin 6 binding to gp130 and activation of STAT-Signaling Pathways independent of Interleukin 6-Receptor. https://www.ncbi.nlm.nih.gov/pubmed/19264784
  2. Ancey C. et al. Cardiovasc Res.2003; 59(1): 78-85.. Human cardiomyocyte hypertrophy induced in vitro by gp130 stimulation.. https://www.ncbi.nlm.nih.gov/pubmed/12829178
  3. Autissier P. et al. Int Immunol.1998; 10(12): 1881-9.. Dimerization and activation of the common transducing chain (gp130) of the cytokines of the IL-6 family by mAb. https://www.ncbi.nlm.nih.gov/pubmed/9885909
  4. Bataille R. et al. Blood1995; 86(2): 685-91.. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. https://www.ncbi.nlm.nih.gov/pubmed/7605999
  5. Bataille R. et al. Med Oncol Tumor Pharmacother.1993; 10(4): 185-8.. Effects of an anti-interleukin-6 (IL-6) murine monoclonal antibody in a patient with acute monoblastic leukemia. https://www.ncbi.nlm.nih.gov/pubmed/8164456
  6. Beck J. T. et al. N Engl J Med.1994; 330(9): 602-5.. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. https://www.ncbi.nlm.nih.gov/pubmed/8302342
  7. Blay J. Y. et al. Blood1993; 82(7): 2261-2.. Role of interleukin-6 in paraneoplastic thrombocytosis. https://www.ncbi.nlm.nih.gov/pubmed/8400277
  8. Blay J. Y. et al. Int J Cancer1997; 72(3): 424-30.. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. https://www.ncbi.nlm.nih.gov/pubmed/9247285
  9. Burger R. et al.Haematologica 2017;102(2) :381-390. Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth. https://www.ncbi.nlm.nih.gov/pubmed/27658435
  10. Burger R.Transfus Med Hemother.2013; 40(5): 336-43. Impact of interleukin-6 in hematological malignancies.. https://www.ncbi.nlm.nih.gov/pubmed/24273487
  11. Choudhary M.M. et al.World J Otorhinolaryngol Head Neck Surg. 2016 Jul 20;2(2):90-97.. Interleukin-6 role in head and neck squamous cell carcinoma progression.. https://www.ncbi.nlm.nih.gov/pubmed/29204553
  12. Choy E. H. et al. Br J Rheumatol.1995; 34(8): 707-15.. Therapeutic monoclonal antibodies. https://www.ncbi.nlm.nih.gov/pubmed/7551652
  13. Choy E. H. et al. Br J Rheumatol.1998; 37(5): 484-90.. Monoclonal antibody therapy in rheumatoid arthritis. https://www.ncbi.nlm.nih.gov/pubmed/9651073
  14. Choy E. Ann Rheum Dis.2003; 62 Suppl 2: ii68-9.. Interleukin 6 receptor as a target for the treatment of rheumatoid arthritis. https://www.ncbi.nlm.nih.gov/pubmed/14532153
  15. Corbellino M. et al. Blood 2001; 98(12): 3473 - 3475. Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. https://www.ncbi.nlm.nih.gov/pubmed/11719390